Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Brain Volume-Related Polymorphisms of the Glycogen Synthase Kinase-3β Gene and Their Effect on Antidepressant Treatment in Major Depressive Disorder.

Sunada N, Takekita Y, Nonen S, Wakeno M, Koshikawa Y, Ogata H, Kinoshita T, Kato M.

Neuropsychobiology. 2019;78(3):136-144. doi: 10.1159/000500614. Epub 2019 Jun 12.

PMID:
31189175
2.

Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis.

Matsui K, Tokumasu T, Takekita Y, Inada K, Kanazawa T, Kishimoto T, Takasu S, Tani H, Tarutani S, Hashimoto N, Yamada H, Yamanouchi Y, Takeuchi H.

Schizophr Res. 2019 Jul;209:50-57. doi: 10.1016/j.schres.2019.05.030. Epub 2019 Jun 8.

PMID:
31182319
3.

Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder.

Kusumi I, Arai Y, Okubo R, Honda M, Matsuda Y, Matsuda Y, Tochigi A, Takekita Y, Yamanaka H, Uemura K, Ito K, Tsuchiya K, Yamada J, Yoshimura B, Mitsui N, Matsubara S, Segawa T, Nishi N, Sugawara Y, Kako Y, Shinkawa I, Shinohara K, Konishi A, Iga J, Hashimoto N, Inomata S, Tsukamoto N, Ito H, Ito YM, Sato N.

BJPsych Open. 2018 Oct 30;4(6):454-460. doi: 10.1192/bjo.2018.56. eCollection 2018 Nov.

4.

Therapeutic Response to Paroxetine in Major Depressive Disorder Predicted by DNA Methylation.

Takeuchi N, Nonen S, Kato M, Wakeno M, Takekita Y, Kinoshita T, Kugawa F.

Neuropsychobiology. 2017;75(2):81-88. doi: 10.1159/000480512. Epub 2017 Nov 4.

PMID:
29131015
5.

Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT.

Kato M, Takekita Y, Koshikawa Y, Sakai S, Bandou H, Nishida K, Sunada N, Onohara A, Hatashita Y, Serretti A, Kinoshita T.

J Psychiatr Res. 2017 Jun;89:97-104. doi: 10.1016/j.jpsychires.2017.02.003. Epub 2017 Feb 3.

PMID:
28213170
6.

Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia?

Takekita Y, Serretti A.

Evid Based Ment Health. 2016 Nov;19(4):e25. doi: 10.1136/eb-2015-102215. Epub 2016 Sep 1. No abstract available.

PMID:
27586196
7.

Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.

Takekita Y, Koshikawa Y, Fabbri C, Sakai S, Sunada N, Onohara A, Nishida K, Yoshimura M, Kato M, Serretti A, Kinoshita T.

BMC Psychiatry. 2016 May 29;16:172. doi: 10.1186/s12888-016-0883-9.

8.

[Vascular dementia: an update].

Yoshimura M, Nishida K, Takekita Y, Kinoshita T.

Nihon Rinsho. 2016 Mar;74(3):489-94. Japanese.

PMID:
27025092
9.

Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials.

Takekita Y, Suwa T, Sunada N, Kawashima H, Fabbri C, Kato M, Tajika A, Kinoshita T, Furukawa TA, Serretti A.

Eur Arch Psychiatry Clin Neurosci. 2016 Dec;266(8):703-717. Epub 2016 Jan 28. Review.

PMID:
26822480
10.

The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial.

Koshikawa Y, Takekita Y, Kato M, Sakai S, Onohara A, Sunada N, Nishida K, Yoshimura M, Fabbri C, Serretti A, Kinoshita T.

Neuropsychobiology. 2016;73(1):35-42. doi: 10.1159/000442209. Epub 2016 Jan 27.

PMID:
26812618
11.

Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 Is Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder: Sequencing Analysis of SLC6A4.

Nonen S, Kato M, Takekita Y, Wakeno M, Sakai S, Serretti A, Kinoshita T.

J Clin Psychopharmacol. 2016 Feb;36(1):27-31. doi: 10.1097/JCP.0000000000000454.

PMID:
26674707
12.

Neuropsychological Evaluation and Cerebral Blood Flow Effects of Apolipoprotein E4 in Alzheimer's Disease Patients after One Year of Treatment: An Exploratory Study.

Suwa A, Nishida K, Utsunomiya K, Nonen S, Yoshimura M, Takekita Y, Wakeno M, Tajika A, Yoshino M, Koshikawa Y, Kato M, Kinoshita T.

Dement Geriatr Cogn Dis Extra. 2015 Oct 22;5(3):414-23. doi: 10.1159/000440714. eCollection 2015 Sep-Dec.

13.

Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients.

Takekita Y, Fabbri C, Kato M, Nonen S, Sakai S, Sunada N, Koshikawa Y, Wakeno M, Okugawa G, Kinoshita T, Serretti A.

Neuropsychobiology. 2015;72(2):118-25. doi: 10.1159/000441629. Epub 2015 Nov 27.

PMID:
26609891
14.

HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis.

Takekita Y, Fabbri C, Kato M, Koshikawa Y, Tajika A, Kinoshita T, Serretti A.

Int J Neuropsychopharmacol. 2016 Apr 29;19(5). pii: pyv125. doi: 10.1093/ijnp/pyv125. Print 2016 May. Review.

15.

Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.

Takekita Y, Fabbri C, Kato M, Nonen S, Sakai S, Sunada N, Koshikawa Y, Wakeno M, Okugawa G, Kinoshita T, Serretti A.

Eur Arch Psychiatry Clin Neurosci. 2015 Oct;265(7):579-88. doi: 10.1007/s00406-015-0605-1. Epub 2015 May 28.

PMID:
26016467
16.

HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia.

Takekita Y, Fabbri C, Kato M, Nonen S, Sakai S, Sunada N, Koshikawa Y, Wakeno M, Okugawa G, Kinoshita T, Serretti A.

J Clin Psychopharmacol. 2015 Jun;35(3):220-7. doi: 10.1097/JCP.0000000000000304.

PMID:
25822479
17.

Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs.

Kato M, Serretti A, Nonen S, Takekita Y, Wakeno M, Azuma J, Kinoshita T.

Transl Psychiatry. 2015 Feb 24;5:e513. doi: 10.1038/tp.2015.6.

18.

Case of adult-onset type II citrullinemia treated as schizophrenia for a long time.

Kyo M, Mii H, Takekita Y, Tokuhara D, Yazaki M, Nakamori Y, Kono S, Kinoshita T.

Psychiatry Clin Neurosci. 2015 May;69(5):306-7. doi: 10.1111/pcn.12253. Epub 2014 Dec 29. No abstract available.

19.

[Current state and vision of the development of new antipsychotic drugs].

Takekita Y, Kinoshita T.

Nihon Rinsho. 2013 Apr;71(4):730-6. Review. Japanese.

PMID:
23678608
20.

5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial.

Kato M, Nonen S, Serretti A, Tetsuo S, Takekita Y, Azuma J, Kinoshita T.

J Clin Psychopharmacol. 2013 Feb;33(1):131-2. doi: 10.1097/01.jcp.0000426182.66701.76. No abstract available.

PMID:
23288236
21.

A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.

Takekita Y, Kato M, Wakeno M, Sakai S, Suwa A, Nishida K, Okugawa G, Kinoshita T.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:110-4. doi: 10.1016/j.pnpbp.2012.09.010. Epub 2012 Sep 27.

PMID:
23022672
22.

Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report.

Kawabata S, Miyatake S, Hiramatsu R, Hirota Y, Miyata S, Takekita Y, Kuroiwa T, Kirihata M, Sakurai Y, Maruhashi A, Ono K.

Appl Radiat Isot. 2011 Dec;69(12):1796-9. doi: 10.1016/j.apradiso.2011.03.014. Epub 2011 Mar 21.

PMID:
21459588
23.

Olfactory reference syndrome treated by blonanserin augmentation.

Takekita Y, Kato M, Sakai S, Suwa A, Nishida K, Tajika A, Yoshimura M, Kinoshita T.

Psychiatry Clin Neurosci. 2011 Mar;65(2):203-4. doi: 10.1111/j.1440-1819.2010.02185.x. No abstract available.

24.

Differences in quantitative EEG between frontotemporal dementia and Alzheimer's disease as revealed by LORETA.

Nishida K, Yoshimura M, Isotani T, Yoshida T, Kitaura Y, Saito A, Mii H, Kato M, Takekita Y, Suwa A, Morita S, Kinoshita T.

Clin Neurophysiol. 2011 Sep;122(9):1718-25. doi: 10.1016/j.clinph.2011.02.011. Epub 2011 Mar 10.

PMID:
21396882
25.

Syndrome of inappropriate secretion of anti-diuretic hormone in an elderly depressive patient receiving paroxetine: a case report.

Suwa A, Wakeno M, Tajika A, Kato M, Sugimoto T, Nishida K, Sakai S, Fujiyama Y, Takekita Y, Kinoshita T.

Int J Geriatr Psychiatry. 2010 Apr;25(4):433-4. doi: 10.1002/gps.2337. No abstract available.

PMID:
20222083
26.

Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects.

Kato M, Okugawa G, Wakeno M, Takekita Y, Nonen S, Tetsuo S, Nishida K, Azuma J, Kinoshita T, Serretti A.

Eur Neuropsychopharmacol. 2009 Oct;19(10):718-25. doi: 10.1016/j.euroneuro.2009.06.006. Epub 2009 Jul 7. Erratum in: Eur Neuropsychopharmacol. 2010 Feb;20(2):137.

PMID:
19586755
27.

[5-HT1A gene polymorphisms contributed to antidepressant response in major depression].

Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Serretti A, Azuma J, Kinoshita T.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2009 Feb;29(1):23-31. Review. Japanese.

PMID:
19326813
28.

The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran.

Wakeno M, Kato M, Okugawa G, Fukuda T, Hosoi Y, Takekita Y, Yamashita M, Nonen S, Azuma J, Kinoshita T.

J Clin Psychopharmacol. 2008 Oct;28(5):518-24. doi: 10.1097/JCP.0b013e31818455fc.

PMID:
18794646
29.

Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder.

Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Watanabe S, Yamashita M, Hosoi Y, Azuma J, Kinoshita T, Serretti A.

Am J Med Genet B Neuropsychiatr Genet. 2009 Jan 5;150B(1):115-23. doi: 10.1002/ajmg.b.30783.

PMID:
18484082
30.

Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.

Kato M, Wakeno M, Okugawa G, Fukuda T, Takekita Y, Hosoi Y, Azuma J, Kinoshita T, Serretti A.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15;32(4):1041-4. doi: 10.1016/j.pnpbp.2008.01.019. Epub 2008 Feb 13.

PMID:
18325652
31.

ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.

Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, Hosoi Y, Takekita Y, Mandelli L, Azuma J, Kinoshita T.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):398-404. Epub 2007 Sep 15.

PMID:
17913323
32.

Delirium associated with paroxetine in an elderly depressive patient: a case report.

Wakeno M, Okugawa G, Takekita Y, Kato M, Fukuda T, Yamashita M, Hosoi Y, Azuma J, Kinoshita T.

Pharmacopsychiatry. 2007 Sep;40(5):199-200. No abstract available.

PMID:
17874351
33.

Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.

Kato M, Fukuda T, Wakeno M, Fukuda K, Okugawa G, Ikenaga Y, Yamashita M, Takekita Y, Nobuhara K, Azuma J, Kinoshita T.

Neuropsychobiology. 2006;53(4):186-95. Epub 2006 Jul 26.

PMID:
16874005

Supplemental Content

Loading ...
Support Center